COMPANY PROFILE

QL Biopharm

Explore full profile

Developing biological drugs for chronic metabolic diseases using recombinant protein technology

ChinaFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About QL Biopharm

QL Biopharm, founded in September 2018, is dedicated to the development of biological drugs targeting chronic metabolic diseases such as diabetes, obesity, and NASH. The company specializes in producing recombinant protein drugs using Escherichia coli, with a robust R&D pipeline featuring 10 innovative drugs and biosimilars. Among these, two international first-class innovative drugs and a large-scale biosimilar are set to enter clinical trials by the end of 2022. The R&D team, comprising experts from renowned pharmaceutical companies like Novo Nordisk and Gan Lee, brings extensive experience in biopharmaceuticals. QL Biopharm's ZT002 injection, a first-in-class drug for controlling blood glucose in type 2 diabetes patients, received clinical application approval in April 2023. The company operates in the biopharmaceutical market, focusing on developing and commercializing drugs that address significant unmet medical needs. Revenue is generated through the development and licensing of these drugs.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: China
Open positions: None listed
Dealroom signal: 23.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Mar 2026	$69M	$275M	Huagai Capital · Apricot Capital · Taiyu Investment · Five Source Capital	↗
SERIES COther financing	Jan 2026	—	—	Legend Star	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

QL Biopharm website traffic

Latest recorded traffic for QL Biopharm is 510 monthly website visits, up 13.3% over the last three months.

Latest monthly visits510 3-month web change+13.3%

Monthly website visitsFeb 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSuzhou Huitherapy Biomedical Technology a high-tech enterprise engaged in the industrialization of comprehensively providing nucleic acid drugs	China	Operational	—	$41M	$138M
RMRVAC MedicinesMRNA platform company engaged in the research and development of innovative products such as vaccines for diseases	Singapore	Operational
BTBiophysical TherapeuticsThis website is for a biotechnology company whose mission is to slow aging and extend healthspan and lifespan	Wilmington, United States	Operational
ATAlamab TherapeuticsClinical Trial Approval in Australia	Princeton, United States	Operational
RHRheavitaContinuous freeze-drying technology for biopharmaceutical products	Ghent, Belgium	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
SOSovargenLeading the way in RNA therapies for brain diseases	Daejeon, South Korea	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational